GPX-100

CAS No. 628290-43-7

GPX-100( —— )

Catalog No. M36121 CAS No. 628290-43-7

GPX-100 (13-deoxydoxorubicin) is an analogue of the anthracycline antitumour antibiotic doxorubicin.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 223 In Stock
10MG 330 In Stock
25MG 557 In Stock
50MG 779 In Stock
100MG 1079 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GPX-100
  • Note
    Research use only, not for human use.
  • Brief Description
    GPX-100 (13-deoxydoxorubicin) is an analogue of the anthracycline antitumour antibiotic doxorubicin.
  • Description
    GPX-100 (13-deoxydoxorubicin) is an analogue of the anthracycline antitumour antibiotic doxorubicin. GPX-100 inserts into DNA and interacts with topoisomerase II to inhibit DNA replication and repair as well as RNA and protein synthesis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    628290-43-7
  • Formula Weight
    529.54
  • Molecular Formula
    C27H31NO10
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    OC=1C2=C([C@@H](O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C[C@@](CCO)(O)C2)C(O)=C4C1C(=O)C=5C(C4=O)=C(OC)C=CC5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • NMDI14

    NMDI14 is an inhibitor of nonsense mediated RNA decay (NMD).

  • FMOC-L-1,2,3,4-TETRA...

    FMOC-L-1,2,3,4-TETRAHYDRONORHARMAN-3-CAR is a chemical compound.

  • Nogo-66 (1-40)

    Peptide fragment corresponding to residues 1 - 40 of Nogo-66, the domain of the myelin protein Nogo that inhibits axonal outgrowth. Acts as a competitive antagonist at the Nogo-66 receptor (NgR); blocks Nogo-66- and CNS myelin-induced inhibition of axonal growth, but does not reduce myelin-associated glycoprotein (MAG) inhibition of neurite outgrowth in vitro. Promotes regeneration of hemisected spinal axons and locomotor recovery following spinal injury in vivo.